FluMist manufacturing facility cited
FDA issues MedImmune a warning letter citing the company for manufacturing deficiencies at its Liverpool, U.K. facility, including failure to implement a program to control microbial contamination of eggs used to make FluMist. FDA does not expect lower availability of the flu vaccine for the 2007-2008 flu season, unlike the 2004-2005 season when GMP violations by Chiron caused a shortage...
You may also be interested in...
Manufacturers of live vaccines such as those for influenza will soon be able to rely solely on process controls and, where necessary, process containment, to prevent cross-contamination of live vaccine organisms, under a recent direct final rule by FDA
The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.
Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.